Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Crinetics Pharmaceuticals Inc.
Sponsor

Crinetics Pharmaceuticals Inc.

United States 6055 Lusk Boulevard, 92121-2700, United States

About the sponsor

Clinical research includes treatment of acromegaly, with attention to control of IGF-1 activity, symptom burden, and longer-term safety and tolerability in adults living with persistent hormone excess.

  • Acromegaly symptom control
  • IGF-1 normalization
  • Long-term safety and tolerability

Work in this area centers on endocrine regulation and disease control in pituitary-driven hormone imbalance.

About Specializations

Crinetics Pharmaceuticals Inc. runs clinical trials in conditions such as Adrenogenital syndrome, Acromegaly, Carcinoid syndrome, Pituitary-dependent Cushing's syndrome, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

11 clinical trials

Adrenogenital syndrome

Recruiting

A Study Testing Atumelnant Compared to Placebo in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Steroid Dose While Controlling Hormones

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Adrenogenital syndrome

Recruiting

A Study of Atumelnant for Children with Congenital Adrenal Hyperplasia

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Adrenogenital syndrome

Recruiting

Study on the Safety and Effectiveness of CRN04894 for Patients with Congenital Adrenal Hyperplasia

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Pituitary-dependent Cushing's syndrome

Not yet recruiting

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Carcinoid syndrome

Not yet recruiting

Efficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Neuroendocrine tumour+1

Not recruiting

A Study of CRN09682 for Patients with Neuroendocrine Tumors and Other Solid Tumors that Express Somatostatin Receptor Type 2

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:CRN09682
  • Sponsor:Crinetics Pharmaceuticals Inc.

Acromegaly

Not recruiting

Study on the Long-Term Safety and Efficacy of Paltusotine for Patients with Acromegaly

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Carcinoid syndrome

Not recruiting

Study on the Safety and Effects of Paltusotine and Octreotide Acetate for Patients with Carcinoid Syndrome

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Octreotide Acetate
  • Sponsor:Crinetics Pharmaceuticals Inc.

Acromegaly

Not recruiting

Study on the Safety and Effectiveness of Paltusotine for Patients with Acromegaly

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Acromegaly

Not recruiting

Study on the Effects of Paltusotine for Patients with Untreated Acromegaly

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Adrenogenital syndrome

Not recruiting

Study on the Safety and Effectiveness of CRN04894 for Patients with Congenital Adrenal Hyperplasia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Crinetics Pharmaceuticals Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.